The Global Drug Discovery Informatics Market is projected to reach $4.81 billion by 2028, from a value of $2.67 billion in 2022, by registering a CAGR of 10.3% during the forecast period. The growing investment in research development into informatics by the pharmaceutical & biotechnology industries, the development of new insilico tools by several leading companies and the growing prevalence of chronic diseases such as cardiovascular diseases, oncology, diabetes mellitus, and other infectious diseases are the major factors propelling the growth of the market. However, high setup costs of informatics software and high installation cost are hampering the market growth. Moreover, increased use for cloud-based services is creating ample opportunities across the globe.
Recent Developments
In September 2019, Evotec collaborated with Takeda Pharmaceutical Company Limited to establish five drug discovery programs with clinical candidates from Evotec for further clinical development by Takeda across multiple therapy areas.
In May 2022, PostEra, collaborated with the National Institutes of Health to develop small molecule antiviral therapeutics to prevent pandemics. PostEra co-leads this initiative with the Drugs for Neglected Diseases Initiative, a global charity with expertise in drug development for global equitable access, and the Memorial Sloan Kettering Cancer Center. The consortium is committed to making resulting antivirals globally and equitably accessible, so that no patient population is left behind.
In May 2022, ICT provider Fujitsu has partnered with research institute Riken in Japan to jointly work on new-generation IT drug discovery technology to accelerate digital transformation in drug discovery.
In February 2022 Dante Labs, signed agreement with the Renato Dulbecco Foundation focused on cancer, COVID-19, and uncommon disorders. Dante, the organization, has licensed from biotech firm Protelica a library of billions of pronectin nanoantibodies and related intellectual property. The foundation will employ Dante’s next-generation sequencing data analysis platform to uncover nanoantibodies that can be used for various therapeutic purposes, including the treatment of COVID-19 and orphan diseases, under the terms of their collaboration.
Competitive Landscape
Tata Consultancy Services Limited, Dante Labs, Schrödinger LLC., PerkinElmer Inc., Oracle, Novo Informatics, Evotec , International Business Machines Corporation (IBM), Infosys Limited, Informatics Matters Ltd., Illumina Inc, Eurofins DiscoverX Products, CORE INFORMATICS, Collaborative Drug Discovery, ChemAxon Ltd., PostEra, Certara, Boehringer Ingelheim International GmbH, Amazon Web Services, Albany Molecular Research Inc., Agilent Technologies Inc., Accenture, Fujitsu are some of the major players in the Global Drug Discovery Informatics Market.
